N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-6-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-6-carboxamide
• 英文别名: N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-1H-indazole-6-carboxamide
• 化学式: C₁₅H₁₈N₄O
• 分子量: 270.334
• InChiKey: OYCAIFKXULCOPU-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  61
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
  申请人：——

  公开号：US20030073707A1

  公开（公告）日：2003-04-17

  The invention provides compounds of Formula I: 1 wherein W 0 is a bicyclic moiety and is 2 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中W0是一个双环基团，是 这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物，对治疗已知涉及α7的疾病或症状有用。
• Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
  申请人：——

  公开号：US20040132790A1

  公开（公告）日：2004-07-08

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the &agr;7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明通常涉及乙酰胆碱受体配体（nAChR）、nAChR激活以及与缺陷或功能障碍的乙酰胆碱受体相关的疾病状态的治疗领域，特别是大脑。此外，本发明涉及新型化合物（吲唑和苯并噻唑），其作为α7 nAChR亚型的配体，制备此类化合物的方法，含有此类化合物的组合物，以及使用此类化合物的方法。
• INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF
  申请人：Xie Wenge

  公开号：US20080154037A1

  公开（公告）日：2008-06-26

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明涉及尼古丁乙酰胆碱受体(nAChR)的配体、nAChR的激活以及与缺陷或功能失常的尼古丁乙酰胆碱受体相关的疾病状态的治疗，特别是大脑的治疗。此外，本发明涉及新型化合物(吲唑和苯并噻唑)，其作为α7 nAChR亚型的配体，制备此类化合物的方法，包含此类化合物的组合物以及使用此类化合物的方法。
• Indazoles, Benzothiazoles, and Benzoisothiazoles, and preparation and uses thereof
  申请人：Memory Pharmaceuticals Corporation

  公开号：EP2305675A1

  公开（公告）日：2011-04-06

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the alpha7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明一般涉及烟碱乙酰胆碱受体（nAChR）的配体、nAChR 的活化以及与烟碱乙酰胆碱受体缺陷或功能失调相关的疾病（尤其是脑部疾病）的治疗领域。此外，本发明还涉及作为α7 nAChR亚型配体的新型化合物（吲唑类和苯并噻唑类）、制备此类化合物的方法、含有此类化合物的组合物及其使用方法。
• QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1404674A2

  公开（公告）日：2004-04-07